Cogent Biosciences (COGT) risk factors
Item 1A of every Cogent Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors60 risks17 new2 dropped10 reworded
Cogent is expanding its headcount from 164 to 258 employees and adding up to 100 commercial roles to prepare for the U.S. launch of bezuclastinib. The company has $230.0 million in outstanding Convertible Notes due in 2026 bearing a fixed 1.625% interest rate. Regulatory filings are advancing with an NDA submitted for NonAdvSM in 2025, a GIST NDA submission initiated in January 2026, and an AdvSM NDA planned for the first half of 2026.
Filed Feb 17, 2026 - FY2024 10-K risk factors45 risks
Cogent Biosciences relies heavily on the clinical and commercial success of its single lead drug candidate, bezuclastinib, targeting SM and GIST. The company depends entirely on single-source suppliers for bezuclastinib raw materials and faces substantial ongoing financial losses requiring future capital.
Filed Feb 25, 2025